MorphoSys AG: MorphoSys and Incyte Announce Additional Real-

- RE-MIND2 compared patient outcomes from pivotal L-MIND study with matched patient populations treated with NCCN/ESMO recommended therapies- Results from the retrospective cohort analysis indicate significant

Related Keywords

Delaware , United States , Germany , Boston , Massachusetts , Georgia , Munich , Bayern , Atlanta , American , Grzegorz Nowakowski , Peter Langmuir , Nuwan Kurukulasuriya , Practice Research Clinical Haematology , Janssen Biotech Inc , American Society Of Hematology Annual Meeting , Xencor Inc , Group Vice , Drug Administration , Global Head Of Medical Affairs , Janssen Research Development , Morphosys Us Inc , Exchange Commission , Meeting Of The Society Hematologic Oncology , European Medicines Agency , Hematologic Oncology , American Society , Hematology Annual Meeting , Mayo Clinic , Senior Vice President , Global Head , Medical Affairs , Group Vice President , Oncology Targeted Therapies , Diffuse Largeb Cell Lymphoma , National Comprehensive Cancer , European Society , Medical Oncology , Antibody Dependent Cell Mediated Cytotoxicity , Antibody Dependent Cellular Phagocytosis , Medication Guide , Patient Information , Important Safety , Janssen Research , Janssen Biotech , Morphosy Annual Report , Practice Research , Morphosys , Incyte , Nnounce , Dditional , Meal , World , Evidence , Results , Rom , Ind2 , Study , Tafasitamab , Monjuvi , Combination , Lenalidomide , Treatment , Relapsed , Refractory , Diffuse , Barge , Fell , Gym ,